Unicycive Therapeutics, Inc. UNCY
3.70 USD +0.11 (+3.06%)
Nov 4, 2026, 2:41 PM EST
3.63 Day range 3.79
3.33 52-week range 8.74
- YTD
- -35.88%
- 1 year
- -16.67%
Analyst view
Price target (mean) 5.50 +48.6% upside
Now 3.70
- Target (low)
- 2.00
- Target (mean)
- 5.50
- Target (high)
- 9.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.07 | -0.09 – -0.05 | -0.16 | +56.3% | 0 | 0.0% | 5 |
| Next quarter | -0.075 | -0.10 – -0.06 | -0.61 | +87.7% | 0 | 0.0% | 4 |
| Current year | -0.53 | -0.89 – -0.37 | -1.28 | +58.6% | 0 | -100.0% | 6 |
| Next year | -0.344 | -0.49 – -0.15 | -0.53 | +35.1% | 32.50M | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 22, 2024 | Benchmark | Reiterated | Speculative Buy | Speculative Buy |
| Nov 14, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 9, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 6, 2024 | Benchmark | Reiterated | Speculative Buy | Speculative Buy |
| Sep 3, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 25, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 3, 2024 | Benchmark | Reiterated | Speculative Buy | Speculative Buy |
| May 31, 2024 | Benchmark | Reiterated | Speculative Buy | Speculative Buy |
| May 29, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 15, 2024 | Benchmark | Reiterated | Speculative Buy | Speculative Buy |
| Apr 4, 2024 | Piper Sandler | Initiated | — | Overweight |
| Apr 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 5, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 14, 2024 | Noble Capital Markets | Initiated | — | Outperform |
| Dec 19, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 4, 2023 | Benchmark | Reiterated | Speculative Buy | Speculative Buy |
| Aug 16, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 19, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 30, 2023 | EF Hutton | Reiterated | Buy | Buy |
| Jun 30, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 26, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 20, 2023 | Benchmark | Reiterated | Speculative Buy | Speculative Buy |
| May 17, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 17, 2023 | EF Hutton | Reiterated | Buy | Buy |